Skip to main content
. 2018 Jan 10;29(3):1049–1062. doi: 10.1681/ASN.2017060679

Figure 7.

Figure 7.

CD80 and CD86 expression varies according to the maturation stages of circulating B cells and KTRs treated with Belatacept display decreased CD80 expression on B cells, particularly on memory B cells. (A) Staining of CD19+ B cells with CD80 and CD86 antibodies (upper panel) and isotype control (lower panel). (B and C) Proportions of (B) CD80+ and (C) CD86+ B cells of HBDs were evaluated according to B cell subsets described in Figure 6A (n=10). Data are given as mean±SEM for each group. *P<0.05 memory versus mature B cells (Kruskal–Wallis test); #P<0.05 memory versus transitional B cells (Kruskal–Wallis test); &P<0.05 transitional versus mature B cells (Kruskal–Wallis test). (D) CD80 proportion and (E) MFI in B cells of HBDs (n=10) or KTRs treated with CNI (n=12) or Belatacept (n=10) described in Table 1. (F) CD80 proportion and (G) MFI in memory B cells of patients described above. Data are given as mean±SEM for each group. Bela, Belatacept. *P<0.05 versus CNI (Kruskal–Wallis test); #P<0.05 versus HBD (Kruskal–Wallis test).